Moderna Outlines Strategy to Address SARS-CoV-2 Variants; Ships Variant Booster to NIH for Testing
The NIAID will evaluate the vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant, B.1.351.
The NIAID will evaluate the vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant, B.1.351.
In mass vaccination setting, vaccine is effective for symptomatic COVID-19, hospitalization, severe disease, death
TicoVac is an inactivated whole virus vaccine developed using a master ‘seed’ virus that is similar to the tick-borne encephalitis virus found in nature.
Most makers of approved COVID-19 vaccines have said they plan to adapt their vaccines to tackle variants
Study among health care workers shows reductions in SARS-CoV-2 infection rates one to 14, 15 to 28 days after first dose of the BNT162b2 COVID-19 vaccine
Findings from the first month show no unexpected adverse events, with 6,994 adverse events and >90 percent classified as nonserious
The ACIP emphasizes the importance of routine vaccinations during the pandemic to prevent diseases.
The randomized, placebo-controlled, observer-blind study is evaluating the safety, tolerability, and immunogenicity of BNT162b2 in approximately 4000 healthy pregnant women aged 18 years and older who are 24 to 34 weeks’ gestation.
Pfizer and Moderna conducting trials of their vaccines in children 12 and older and hope to have findings by the summer
However, data are from survey conducted prior to U.S. emergency use authorization of any vaccines